glp-1 obesity drug news october 2025 Market Size to Hit USD 66.57 Billion by 2035 What to watch for in

The retrospective cohort study by Orandi et al., recently published in The Lancet Diabetes & Endocrinology , offers compelling evidence on the effectiveness and safety of glucagon-like peptide-1 (GLP-1) receptor agonists in kidney transplant recipients with pre-existing type 2 diabetes (1)

Liraglutide was an exception as it also decreased the AUC [24]

The peptide stimulates fat breakdown and inhibits fat storage

It has attracted significant, sustained attention in in-vitro research focused intensely on connective tissue, skeletal muscle fibers, tendons, ligaments, and highly specialized gastrointestinal tissue models